Phase II Eastern Cooperative Oncology Group Study of spirogermanium in previously treated lymphoma.
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D004341:Drug Evaluation; D005857:Germanium / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008223:Lymphoma / Q000188:drug therapy*; D008875:Middle Aged; D009942:Organometallic Compounds; D012640:Seizures / Q000139:chemically induced; D013141:Spiro Compounds / Q000009:adverse effects / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D009942:Organometallic Compounds; D013141:Spiro Compounds; D005857:Germanium; C026818:spirogermanium